https://www.healthcaretribunefrance.com/article/907084823-strategic-expansion-into-continental-europe Healthcare Tribune France en PressRelease 2026-04-21T07:14:26+00:00 Strategic Expansion into Continental Europe https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/18085360-vidac-pharma-1500x767.jpeg https://www.healthcaretribunefrance.com/article/906998846-abivax-annual-ordinary-and-extraordinary-general-meeting-of-may-11-2026-availability-of-the-preparatory-documents Healthcare Tribune France en PressRelease 2026-04-20T20:05:00+00:00 Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.healthcaretribunefrance.com/article/906993005-ab-science-nouvelle-publication-sur-medrxiv-d-montrant-des-b-n-fices-substantiels-en-termes-de-survie-et-de-qualit-de-vie-pr-serv-e-avec-le Healthcare Tribune France en PressRelease 2026-04-20T19:32:18+00:00 AB Science : Nouvelle publication sur medrxiv démontrant des bénéfices substantiels en termes de survie et de qualité de vie préservée avec le masitinib chez les patients atteints de SLA https://ml-eu.globenewswire.com/media/90d86a0e-7ea1-47ab-99d9-69985fa76ce0/small/ https://www.healthcaretribunefrance.com/article/906993019-ab-science-new-publication-on-medrxiv-demonstrating-substantial-survival-benefits-and-preserved-quality-of-life-with-masitinib-in-als-patients Healthcare Tribune France en PressRelease 2026-04-20T19:32:18+00:00 AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients https://ml-eu.globenewswire.com/media/90d86a0e-7ea1-47ab-99d9-69985fa76ce0/small/logo-jpg.jpg https://www.healthcaretribunefrance.com/article/906895935-nanobiotix-annonce-de-nouvelles-donn-es-pr-cliniques-d-montrant-une-am-lioration-de-la-biodisponibilit-syst-mique-et-la-r-duction-de-la-toxicit-pour Healthcare Tribune France en PressRelease 2026-04-20T06:30:00+00:00 Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après traitement avec sa technologie de… https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.healthcaretribunefrance.com/article/906896055-nanobiotix-announces-new-preclinical-data-supporting-improved-systemic-bioavailability-and-reduced-toxicity-for-lnp-delivered-dna-immunotherapy-after Healthcare Tribune France en PressRelease 2026-04-20T06:30:00+00:00 Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.healthcaretribunefrance.com/article/906891437-reminder-last-exercise-day-for-nicox-june-2024-warrants-is-june-19-2026 Healthcare Tribune France en PressRelease 2026-04-20T05:30:00+00:00 Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026 https://ml-eu.globenewswire.com/media/c4c68e53-e467-4048-b580-d1596c4d6d8e/small/logo-png.png https://www.healthcaretribunefrance.com/article/906891441-rappel-le-dernier-jour-d-exercice-pour-les-bons-de-souscription-d-actions-bsa-nicox-de-juin-2024-est-le-19-juin-2026 Healthcare Tribune France en PressRelease 2026-04-20T05:30:00+00:00 Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026 https://ml-eu.globenewswire.com/media/c4c68e53-e467-4048-b580-d1596c4d6d8e/small/